SCHEMBL7439094

SCHEMBL7439094

NCCSC(c1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 3/20 1.00
SLC6A4 P31645 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2C19 P33261 2/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
HRH1 P35367 2/20 0.48
HTR2A P28223 2/20 0.46
TAAR1 Q96RJ0 2/20 0.46
KIF11 P52732 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7438013 0.98 SLC6A3 (0.96) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL9771151 0.90 SLC6A3 (0.81) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL9829609 0.89 SLC6A3 (0.79) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL9771072 0.87 SLC6A3 (0.76) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL11013503 0.87 SLC6A3 (0.77) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL9217623 0.80 SLC6A4 (0.66) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL17432205 0.80 SLC6A4 (0.68) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL9865463 0.80 SLC6A4 (0.67) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL16011789 0.78 SLC6A4 (1.00) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19
SCHEMBL16012142 0.78 SLC6A4 (0.66) SLC6A3SLC6A4CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0097546-B1 BENZHYDRYLSULFINYL ETHYL AMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY LABORATOIRE L. LAFON Société anonyme dite: (FR) 1985-09-25 EP claimed
EP-0097546-A1 Benzhydrylsulfinyl ethyl amines, process for their preparation and their use in therapy LABORATOIRE L. LAFON Société anonyme dite: (FR) 1984-01-04 EP claimed
US-11555013-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) 2023-01-17 US disclosed
EP-2964611-B1 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF US HEALTH (US) 2022-10-19 EP disclosed
EP-2964611-B1 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF US HEALTH (US) 2022-10-19 EP disclosed
US-20210130288-A1 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2021-05-06 US disclosed
US-20210130288-A1 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2021-05-06 US disclosed
US-10913711-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-02-09 US disclosed
US-10913711-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-02-09 US disclosed
US-10590074-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-03-17 US disclosed
US-10590074-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-03-17 US disclosed
US-5171752-A BENZHYDRYL DERIVATIVES HAVING CALMODULIN INHIBITOR PROPERTIES AKZO N.V. (NL) 1992-12-15 US disclosed
EP-0467435-A2 Benzhydryl derivatives having calmodulin inhibitor properties Akzo Nobel N.V. (NL) 1992-01-22 EP disclosed
EP-0302896-B1 N-(W-SUBSTITUTED ALKYL)-N'-[(IMIDAZOLE-4-YL)ALKYL]GUANIDINE CEDONA PHARMACEUTICALS B.V. (NL) 1991-08-14 EP disclosed
US-5010095-A Antiallergens, congestive heart failure CEDONA PHARMACEUTICALS B.V. (NL) 1991-04-23 US disclosed
EP-0135160-B1 BISAMIDE BISTHIOL COMPOUNDS USEFUL FOR MAKING TECHNETIUM RADIODIAGNOSTIC RENAL AGENTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1989-04-26 EP disclosed
EP-0302896-A1 N-(W-SUBSTITUTED ALKYL)-N'-[(IMIDAZOLE-4-YL)ALKYL]GUANIDINE. CEDONA PHARM BV (NL) 1989-02-15 EP disclosed
WO-1987007891-A1 N-(2-SUBSTITUTED ALKYL)-N'-[(IMIDAZOLE-4-YL)ALKYL]GUANIDINE CEDONA PHARMACEUTICALS B.V. (NL) 1987-12-30 WO disclosed
EP-0097546-B1 BENZHYDRYLSULFINYL ETHYL AMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY LABORATOIRE L. LAFON Société anonyme dite: (FR) 1985-09-25 EP disclosed
EP-0097546-A1 Benzhydrylsulfinyl ethyl amines, process for their preparation and their use in therapy LABORATOIRE L. LAFON Société anonyme dite: (FR) 1984-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590074-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof SLC6A2, SLC6A4, SLC6A3 SLC6A3 3/4885SLC6A4 2/4885CYP1A2 580/4885
US-20210130288-A1 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF SLC6A2, SLC6A4, SLC6A3 SLC6A3 3/4885SLC6A4 2/4885CYP1A2 580/4885
US-11555013-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof SLC6A2, SLC6A4, SLC6A3 SLC6A3 3/4885SLC6A4 2/4885CYP1A2 580/4885
US-10913711-B2 Potent and selective inhibitors of monoamine transporters; method of making; and use thereof SLC6A2, SLC6A4, SLC6A3 SLC6A3 3/4885SLC6A4 2/4885CYP1A2 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.